<DOC>
	<DOCNO>NCT02084446</DOCNO>
	<brief_summary>This 12-month single center , randomize , open-label , single center study design compare safety efficacy everolimus low dose tacrolimus versus enteric-coated sodium mycophenolate low tacrolimus exposure de novo kidney transplant recipient . The purpose study compare safety efficacy two immunosuppressive regimen base low tacrolimus exposure combine everolimus enteric-coated mycophenolate sodium ( EC-MPS ) de novo kidney transplant recipient .</brief_summary>
	<brief_title>Everolimus + Very Low Tacrolimus v Enteric-coated Mycophenolate Sodium + Low Tacrolimus de Novo Renal Transplant</brief_title>
	<detailed_description>The study consist two period : initial period 3 month patient group monitor accordance variation C-0h tacrolimus second study period 9 month ( month 4 month 12 ) patient monitor accord two different target C-0h tacrolimus . At screen visit assessment relate study , patient must give informed consent writing . All patient receive induction rabbit Thymoglobulin ( r-ATG ) four dose 1.5 mg/kg ( maximum total dose 6 mg/kg ) , administer accord center local practice . The evaluation baseline visit occur within 24 hour transplantation prior first dose study drug . Randomization perform within 24 hour transplantation baseline visit assessment . Patients randomize 1:1 ratio one two group ( everolimus low dose tacrolimus versus sodium mycophenolate low dose tacrolimus ) . Approximately 120 patient meet inclusion criterion receive first dose everolimus ( initial dose 1 mg twice day ) sodium mycophenolate ( initial dose 720 mg twice day ) 24 hour transplantation . Everolimus trough blood level measure pre-specified timepoints order ensure trough level 3 ng/ml 8 ng/ml duration study . Tacrolimus start within 48 hour graft reperfusion initial dose 0.1 mg/kg/day . The dose tacrolimus adjust target C-0h value within pre-established desired range . In everolimus group low dose tacrolimus , tacrolimus dose reduced end month three transplantation . Patients either acute rejection grade ≥ Banff IIB one treat acute rejection since enter study patient either acute rejection third month dose tacrolimus reduce ; however , encourage remain study . These patient exclude per protocol population analysis , analyze Intention To Treat population . If patient present delay graft function ( DGF ) , start tacrolimus postpone include 7 day . During 12 month treatment period , patient visit occur selection visit , baseline visit , 1 , 2 , 4 8 week 3 , 6 12 month . Day 1 day first administration everolimus sodium mycophenolate . Population : Study population consist group male female transplant recipients 18-75 year age undergoing primary renal transplantation receive organ live deceased donor .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Male female renal recipient 1875 year age undergoing kidney transplantation , primary decease donor ( include expand criterion donor organ ) , live unrelated nonHLA identical living relate donor kidney ; Recipient kidney cold ischemia time &lt; 30 hour ; Graft must functional ( produce great equal 300 ml urine within 24 hour transplantation ) time randomization . Donor organ cold ischemic time &gt; 30 hour ; Patients produce less 300 ml urine first 24 hour posttransplantation ; Patients recipients multiple organ transplant ; Patients recipient ABO incompatible transplant , T B cell cross match positive transplant ; Patients current Panel Reactive Antibodies ( PRA ) level ≥ 50 % ; Patients severe hypercholesterolemia ( 350 mg/dl ) hypertriglyceridemia ( 500 mg/dl ) . Patients lipid lower treatment control hyperlipidemia acceptable ; HIV positive patient ; Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception ; Decisional impair subject medically mentally capable provide consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Sodium Mycophenolate</keyword>
	<keyword>CMV</keyword>
	<keyword>Graft function</keyword>
	<keyword>Acute rejection</keyword>
</DOC>